One device.
Four markets.
One patent family.

The problem it solves shows up everywhere thick fluid meets a thin needle — in aesthetics, orthopaedics, spine surgery and at-home biologics.

Talk to us Download overview (PDF)
The problem

Thick fluid. Thin needle.

Push a viscous fluid through a fine needle and three things go wrong at once: it takes far more force, the clinician loses feel for what is happening at the tip, and any safety check that depends on fluid flowing back stops working altogether.

16×
Halve the needle bore and resistance rises sixteenfold. Flow resistance scales with viscosity, and with the fourth power of the radius.
0%
Aspiration success through a 29G needle primed with hyaluronic acid filler — the safety check that is supposed to detect a blood vessel.
45–90k cP
Typical viscosity range of dermal fillers and knee viscosupplements — orders of magnitude thicker than saline, which sits near 1 cP.
The device

Two barrels. One needle. A switch between them.

  1. One barrel holds the thick payload — filler, viscosupplement, bone cement or a concentrated biologic.
  2. The second holds a low-viscosity fluid, typically saline.
  3. A shared adapter with a switchable valve connects both barrels to a single needle.
  4. Flush the thin fluid first for a clear, fast answer — then switch and inject. The needle never moves between the two steps.

No syringe swap. No second pair of hands. No losing the position you have just found.

Concept animation of the dual-barrel device and its switching mechanism.
The evidence

0% to 100%, in one to two seconds

In controlled in-vitro testing across six commercial hyaluronic acid fillers, blood aspiration through a 29G needle failed every single time when the needle was primed with filler. After a brief low-viscosity flush, it succeeded every time — within one to two seconds.

Scope of the evidence, stated plainly. This result is published and peer-reviewed (Kogan, Korolik, Cartier, Adhoute & Liberzon, Journal of Cosmetic Dermatology, 2020) and it establishes the core physics: a low-viscosity fluid restores flow and feedback through a needle that a viscous payload has effectively blocked. That mechanism transfers directly to other high-viscosity injections. It is not, however, a clinical outcome study in those other fields, and we do not present it as one. Applications beyond dermal fillers are at the concept and development stage.

The markets

The same physics, four times over

Each of these fields has a documented, quantified problem that comes down to controlling a viscous fluid through a narrow lumen.

Market 01

Dermal fillers

0%
aspiration success, 29G needle, unflushed

Injecting filler into a vessel can cause tissue necrosis and, rarely, blindness. The check meant to prevent it does not work through a fine needle.

Buyer: filler manufacturers
Market 02

Knee osteoarthritis

70–84%
of blind knee injections reach the joint

Ultrasound guidance reaches 95–96%, but most injections are given blind. A full course costs the patient $1,000–2,500.

Buyer: viscosupplement manufacturers
Market 03

Bone cement

18–55%
cement leakage in vertebroplasty & kyphoplasty

Cement must be thin enough to inject and thick enough not to leak. Surgeons manage that trade-off by hand, in stages.

Buyer: spine & cement kit makers
Market 04

Self-injected biologics

#1
FDA's most common autoinjector use error

Biologics are concentrated so patients inject less volume. Thicker means more force — through the same 27–29G needles already tested.

Buyer: device makers & pharma
Intellectual property

One patent family. Three separable claims.

The claims cover distinct problems and can be licensed independently, by field or by territory.

FR
Granted
CN
Granted
EU
Examination advanced
US
Pending
01Verify with a low-viscosity fluid when the payload itself cannot give feedback — the mechanism validated in the 2020 publication.
02Switch between two fluids through one shared outlet, via a shutter valve, with six mechanical embodiments claimed.
03Purge the line with a sacrificial fluid rather than wasting an expensive payload.

Patents assigned to AH2I Medical Group Ltd; assignment recordal in progress. Full patent numbers and family details supplied on request under NDA.

The team

Fluid mechanics, clinical practice, and device commercialisation

Dr. Hertsel Adhoute
Dr. Hertsel Adhoute
Co-founder & CEO
Physicist. Thirty years in non-invasive dermatological technology; serial entrepreneur and international consultant.
Dr. Inna Kogan
Dr. Inna Kogan
Co-founder & Medical Adviser
Over twelve years practising cosmetic facial injection. MD, Ben-Gurion University, Israel.
Dr. Hugues Cartier
Dr. Hugues Cartier
Medical Director
Dermatologist. Vice-President of the French Society of Aesthetic Medicine; wound care lead, Arras Hospital.
Prof. Alex Liberzon
Prof. Alex Liberzon
Co-founder & CSO
Heads the Fluid Mechanics Laboratory at Tel Aviv University. Experimental fluid mechanics and flow measurement.

Company. AH2I Medical Group Ltd is an Israeli company (Reg. 517060976), continuing work begun as Syrengy in Marseille, France. Recipient of an Israel Innovation Authority Tnufa grant.

Get in touch

We are looking for two kinds of people

Device & drug-delivery companies

Building high-viscosity injection or delivery platforms, and looking at mechanisms rather than reformulation.

Investors & strategic acquirers

Backing medtech at the platform stage, or acquiring IP with claims that read across multiple fields.

Dr. Hertsel Adhoute

Co-founder & CEO, AH2I Medical Group Ltd

Message on LinkedIn Overview PDF